PFM Health Sciences’s Stevanato STVN Stock Holding History

PFM Health Sciences’s Portfolio STVN Stock Details STVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-549,002	Closed	-$13.9M	–	87
2021 Q3	$13.9M	Buy	+549,002	New	+$12.9M	0.41%	57

Other funds holding STVN

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

MGM

Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PFM Health Sciences's STVN Position: Q4 2021 in Review

PFM Health Sciences sold out of Stevanato (STVN) in Q4 2021, closing a stake of 549,002 shares — an estimated $13.9M sold.

PFM Health Sciences first reported a position in STVN in Q3 2021 and held it in 1 quarter. The position peaked at $13.9M in Q3 2021. 78 funds tracked by Wall St. Rank hold STVN as of Q4 2021.

PFM Health Sciences reported no remaining Stevanato position as of Q4 2021 after selling out during the quarter.
PFM Health Sciences sold 549,002 Stevanato shares in Q4 2021, an estimated $13.9M.
PFM Health Sciences first reported a position in Stevanato in Q3 2021 and held it in 1 quarter.
PFM Health Sciences's Stevanato position peaked at $13.9M in Q3 2021.
78 funds tracked by Wall St. Rank held Stevanato as of Q4 2021.

Based on PFM Health Sciences's 13F filing for Q4 2021, filed 14 Feb 2022.